pQz*6i t{ + ?A?s}AR :c-`T(Bg%`s 5q1N` % B@(SZ &p3BM@||` h^(f)#fFi(i) KF&U )e=d%)))e 4\ +5B0^\BM -&Qv $&#cA#&0m$&A$c8pd$B ZCfCc RS&7#7R Lt1YeywtYDw ~DZcDf*, |=CC+. Zan d%-9cu- du u^# NyN o=QBB CmCf#5g5 [- OX*s _X}?; $nA tzu)u?]u% Du OUqc Xy:XrzttX.

Zanubrutinib demonstrated significantly higher overall response (ORR) and superior progression-free survival (PFS) over ibrutinib in patients with R/R CLL. This PFS benefit was reported across all major subgroups, including the del(17p)/LkNq^B+s population. Zanubrutinib has a favorable safety profile compared with ibrutinib, including a lower rate of grade ≥3 and serious adverse events (AEs) as well as fewer AEs leading to treatment discontinuation and dose reductions. Zanubrutinib has a better cardiac safety profile than ibrutinib with lower rates of atrial fibrillation, serious cardiac events, cardiac events leading to treatment discontinuation, and fewer fatal cardiac events.